Zevra Therapeutics Inc. (ZVRA) made headlines yesterday with a landmark FDA approval for its innovative drug, MIPLYFFA, in the treatment of Niemann-Pick disease type C. The regulatory development not only offers new hope for patients with this ultra-rare and progressive neurodegenerative disease but has also propelled Zevra shares to a new 52-week high.
In addition to ZVRA, a couple of stocks we featured on our site also touched new 52-week highs yesterday.
*Last Closing Price refers to the stock's closing price on Sep.20, 2024.
Ticker
Published Date
Published Price
Maximum Price Since Publication
*Last Closing Price
Maximum Gain %
Zevra Therapeutics Inc. (ZVRA)
Aug.26, 2024
$7.21
$8.81
$8.06
22%
Arcellx Inc. (ACLX)
June 3, 2022
$12.66
$88.17
$86.61
596%
Rockwell Medical Inc. (RMTI)
Sep.4, 2024
$3.21
$4.57
$4.40
42%
Catalyst Pharmaceuticals Inc. (CPRX)
Feb.13, 2024
$13.32
$21.67
$20.79
62%
ADMA Biologics Inc. (ADMA)
Feb.15, 2024
$5.36
$20.16
$19.98
276%
Zymeworks Inc. (ZYME)
Oct.9, 2023
$6.38
$13.23
$13.09
107%
The Pennant Group Inc. (PNTG)
Feb.7, 2023
$12.38
$36.33
$35.68
193%
Travere Therapeutics Inc. (TVTX)
Aug.14, 2024
$8.91
$15.26
$15.21
71%
Related Reading
EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot?
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.